Obesity Management

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.

Obesity-related ischemic heart disease deaths rose from 1999 to 2020, particularly in middle-aged men and Black adults, per CDC WONDER data.

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

A new study finds visceral adipose tissue and subcutaneous adipose tissue are linked to chronic musculoskeletal pain in both sexes but have a stronger association in females.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

Semaglutide lowers rates of cardiovascular and COVID-19-related deaths in patients with overweight/obesity, offering promising cardio-metabolic and non-cardiovascular benefits.

A new study revealed children who go from normal weight to overweight have a greater risk of atopic dermatitis than obese children who maintain their weight.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

A study of 18,000 patients showed tirzepatide (Mounjaro) led to more significant weight loss than semaglutide (Ozempic) in adults with overweight or obesity.

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

Tirzepatide reduces OSA severity by 30 events/hour and achieves remission in up to 51% of patients with obesity, per SURMOUNT-OSA study results from Eli Lilly and Company.

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.